Review



ibs plasma intercept blood systems  (Cerus Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Cerus Inc ibs plasma intercept blood systems
    Ibs Plasma Intercept Blood Systems, supplied by Cerus Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ibs+plasma+intercept+blood+systems/intercept+blood+system+ibs/pm25857325-35-165-172
    Average 90 stars, based on 1 article reviews
    ibs plasma intercept blood systems - by Bioz Stars, 2026-09
    90/100 stars

    Images

    Related Articles

    Clinical Proteomics:

    Article Title: Comparative effectiveness of plasma prepared with amotosalen-UVA pathogen inactivation and conventional plasma for support of liver transplantation.
    Article Snippet: These risks may arise from pathogens that escape detection during the window period,2 undetectable pathogens due to low copy number,3 or emerging pathogens for which no tests are available.4-6 Treatment of plasma with amotosalen and UVA light inactivates a broad spectrum of bloodborne pathogens providing a means to mitigate the risk of TTI.7,8 In some countries, plasma prepared with pathogen inactivation (PI) has been implemented to reduce the risk of TTI.9,10 As different PI methods are introduced into routine clinical practice, it is relevant to assess the impact of these interventions on therapeutic efficacy and safety.11 Randomized clinical trials are inherently limited in size and the scope of the patient population included9 and may not fully characterize the experience in routine use for broad patient populations.12 Studies of comparative effectiveness during routine use can be informative to define the efficacy and safety of new types of blood components because they offer the opportunity to examine a larger experience.13 PI treatment of plasma with amotosalen and UVA light, IBS plasma (INTERCEPT Blood Systems, Cerus Corporation, Concord, CA) was introduced into routine practice in some countries in Europe for therapeutic support of patients with congenital and acquired coagulopathies and for therapeutic plasma exchange.10 A randomized clinical trial to evaluate the therapeutic efficacy and safety of IBS plasma for patients with the acquired coagulopathy of liver disease was conducted and included 51 patients undergoing liver transplant.14 Due to the limited number of liver transplant patients enrolled, the study had limited power to compare the effectiveness of conventional and PI plasma for this important subset of patients.

    Drug discovery:

    Article Title: Comparative effectiveness of plasma prepared with amotosalen-UVA pathogen inactivation and conventional plasma for support of liver transplantation.
    Article Snippet: These risks may arise from pathogens that escape detection during the window period,2 undetectable pathogens due to low copy number,3 or emerging pathogens for which no tests are available.4-6 Treatment of plasma with amotosalen and UVA light inactivates a broad spectrum of bloodborne pathogens providing a means to mitigate the risk of TTI.7,8 In some countries, plasma prepared with pathogen inactivation (PI) has been implemented to reduce the risk of TTI.9,10 As different PI methods are introduced into routine clinical practice, it is relevant to assess the impact of these interventions on therapeutic efficacy and safety.11 Randomized clinical trials are inherently limited in size and the scope of the patient population included9 and may not fully characterize the experience in routine use for broad patient populations.12 Studies of comparative effectiveness during routine use can be informative to define the efficacy and safety of new types of blood components because they offer the opportunity to examine a larger experience.13 PI treatment of plasma with amotosalen and UVA light, IBS plasma (INTERCEPT Blood Systems, Cerus Corporation, Concord, CA) was introduced into routine practice in some countries in Europe for therapeutic support of patients with congenital and acquired coagulopathies and for therapeutic plasma exchange.10 A randomized clinical trial to evaluate the therapeutic efficacy and safety of IBS plasma for patients with the acquired coagulopathy of liver disease was conducted and included 51 patients undergoing liver transplant.14 Due to the limited number of liver transplant patients enrolled, the study had limited power to compare the effectiveness of conventional and PI plasma for this important subset of patients.



    Similar Products

    ibs plasma intercept blood systems  (Cerus Inc)
    90
    Cerus Inc ibs plasma intercept blood systems
    Ibs Plasma Intercept Blood Systems, supplied by Cerus Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/ibs+plasma+intercept+blood+systems/intercept+blood+system+ibs/pm25857325-35-165-172
    Average 90 stars, based on 1 article reviews
    ibs plasma intercept blood systems - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results